原发性肝癌TACE后血清VEGF检测的临床价值

目的 探讨原发性肝细胞肝癌（HCC）经导管化疗栓塞（TACE）治疗前后血清血管内皮细胞生长因子（VEGF）表达的检测价值。方法 采用酶联免疫夹心法（ELISA）对38例HCC患者分别于第1次TACE术前1天、术后1周、术后2周、术后1月及术后2月测量其血清VEGF表达水平。结果 术后1天血清VEGF呈一过性增高,术后1周后VEGF的表达降至低谷,于术后2周开始缓慢上升,术后2月血清VEGF值较术后1月更为明显升高。血清VEGF的高表达与TACE后局部复发密切相关,血清VEGF测值越高,其TACE疗效越差。结论 VEGF检测有利于TACE的疗效判断。     

VEGF released from a fibrin biomatrix increases VEGFR‐2 expression and improves early outcome after ischaemia–reperfusion injury

Skeletal ischaemia–reperfusion (I–R) injury may influence patient outcome after severe vascular trauma or clamping of major vessels. The aim of this study was to observe whether locally applied vascular endothelial growth factor (VEGF) in fibrin could induce the expression of VEGF‐receptor‐2 (VEGFR‐2) and improve the outcome after I–R injury. Transgenic mice expressing VEGFR‐2 promoter‐controlled luciferase were used for the assessment of VEGFR‐2 expression. Ischaemia was induced for 2 h by a tension‐controlled tourniquet to the hind limb, followed by 24 h of reperfusion. The animals were locally injected subcutaneously with fibrin sealant containing 20 or 200 ng VEGF; control animals received no treatment or fibrin sealant application. In vivo VEGFR‐2 expression was quantified upon administration of luciferin at several observation times. For oedema and inflammation quantification, wet:dry ratio measurements and a myeloperoxidase assay of the muscle tissue were performed. Laser Doppler imaging showed that ischaemia was present and that the blood flow had returned to baseline levels after 24 h of reperfusion. VEGFR‐2 expression levels in the fibrin + 200 ng VEGF were significantly higher than in all other groups. Granulocyte infiltration was reduced in both treatment groups, as well as reduced oedema formation. These results showed that VEGF released from fibrin had a positive effect on early I–R outcome in a mouse model, possibly via VEGFR‐2. Copyright © 2016 John Wiley & Sons, Ltd.     

血管内皮生长因子及其受体在颈椎病椎体软骨终板中的表达变化

目的： 研究VEGF和VEGFR在终板软骨细胞中的表达，进一步探讨椎间盘退变的发病机理。方法: 应用免疫组化SP染色法检测VEGF和VEGFR在37例颈椎病及11例正常椎体软骨终板中的表达，并对其阳性表达结果进行比较。结果：VEGF在正常终板软骨细胞表达的阳性率为90.9％，与颈椎病终板软骨细胞表达的阳性率（40.5％）相比，差异有显著性 (P<0.05) 。VEGF在正常的终板软骨细胞的表达明显高于退变的终板软骨。VEGFR在正常的终板软骨细胞表达的阳性细胞率为72.7％，与颈椎病终板软骨细胞表达阳性细胞率（37.8％）相比，差异有显著性（P<0.05）。结论：椎体软骨终板的退变过程中VEGF和VEGFR的表达发生明显的变化，终板软骨细胞VEGF分泌的减少导致终板血管芽的维持不足。VEGF参与了椎间盘退变的形成和发展，表明细胞因子在椎间盘退变的发病中可能起非常重要的作用。调节细胞因子VEGF在终板软骨细胞中的表达，可能为椎间盘退变的治疗提供一种新的途径。     

检测肺癌患者血清中肝细胞生长因子 血管内皮生长因子含量的临床意义

目的探讨血清中肝细胞生长因子（HGF）、血管内皮生长因子（VEGF）含量对肺癌的影响,及其各自在判断肺癌种类方面的价值。方法收集40例肺癌患者,12例肺良性病变患者,15例健康对照组人群的血清。采用酶联免疫吸附试验（ELISA）分别测定HGF、VEGF的含量。结果肺良性病变、健康对照组血清中HGF分别为（245±135）、（228±164）ng/L,无明显升高,VEGF分别为（65±32）、（59±28）ng/L,肺癌组HGF[（431±202）ng/L]、VEGF[（165±52）ng/L]均分别高于肺良性病变组及健康对照组,差异有统计学意义（P〈0.01）。两种血管生长因子在不同类型肺癌中的阳性表达比较分析显示,HGF以肺腺癌中表达更明显,VEGF在肺鳞癌患者血清升高更明显（P〈0.01）。结论肺癌患者血清中HGF、VEGF升高,联合检测对肺癌的诊断和鉴别诊断具有重要价值,有望为提高肺癌的早期检出率提供新的依据。     

非小细胞肺癌患者CT灌注成像与血浆色素上皮衍生因子、血管内皮生长因子水平的相关性

目的观察和研究非小细胞肺癌(NSCLC)患者CT灌注成像(CTPI)与血浆色素上皮衍生因子(PEDF)、血管内皮生长因子(VEGF)水平的相关性。方法选取189例疑有肺部占位病变患者作为研究对象,将其中确诊为NSCLC的患者99例作为病例组,确诊为肺部良性病变的患者90例作为对照组。对2组患者的CTPI参数和血浆PEDF、VEGFR水平进行检测和比较。结果病例组患者的各项CTPI参数均显著高于对照组(P0.05)。病例组患者的血浆PEDF水平显著低于对照组,血浆VEGF水平显著高于对照组(P0.05)。随着TNM分期的升高,NSCLC患者的各项CTPI参数和血浆VEGF水平逐渐升高,血浆PEDF水平逐渐下降,差异均有统计学意义(P0.05)。直线相关分析结果显示,NSCLC患者的血浆PEDF、VEGF水平与表面通透性(PS)无相关性(P0.05),血浆PEDF水平与CTPI参数均呈负相关(P0.05),血浆VEGF水平与其他CTPI参数均呈正相关性(P0.05)。结论 NSCLC患者可表现为CTPI参数水平的升高,与患者的临床分期及血浆PEDF、VEGF水平均具有一定的关联性。     

反义血管内皮生长因子对乳腺癌细胞生长的抑制作用

目的　构建表达反义血管内皮生长因子165(VEGF165)的真核表达载体,观察其对人乳腺癌细胞MCF- 7的影响,探讨反义基因治疗乳腺癌的可行性。方法　应用基因重组技术,将人VEGF165cDNA反向克隆入pcDNA3真核表达载体中,构建VEGF165反义基因的真核表达载体,将此表达载体转染人乳腺癌细胞MCF -7,观察转染前后MCF 7的VEGF165表达及细胞生长周期。结果　成功构建出VEGF165反义RNA真核表达载体,反义质粒转染后MCF -7细胞VEGF165表达下降,G1期细胞增加,S期细胞减少,细胞增殖能力降低。结论　VEGF165反义RNA能够明显减少人乳腺癌细胞株MCF- 7内VEGF165的表达,抑制乳腺癌细胞的增殖,证明了反义基因干预治疗的有效性,为乳腺癌的基因治疗进行了有益探索。     

SPHK1、VEGF在胃癌中的表达及其与临床病理特征和预后的关系

目的 探讨鞘氨醇激酶1(SPHK1)与血管内皮生长因子(VEGF)在人胃癌组织中的表达及其与临床病理特征和预后的关系.方法 采用免疫组化SP法检测SPHK1与VEGF蛋白在178例胃癌组织及其162份癌旁组织中的表达情况,使用Kaplan-Meier Plotter数据库了解SPHK1、VEGF对胃癌患者生存时间的影响...     

VEGF在翼状胬肉组织中的表达

目的 检测血管内皮生长因子（VEGF）在翼状胬肉中的表达。方法 应用免疫组化SABC法，分别对15例翼状胬肉标本和12例正常结膜组织中的VEGF表达进行检测。比较2组间的差异。结果 12例正常结膜中，6例为阴性，3例VEGF蛋白染色弱阳性（＋），3例为阳性（＋＋）；15例翼状胬肉组织中，1例VEGF蛋白染色阴性，3例为弱阳性（＋），7例为阳性（＋＋），5例为强阳性（＋＋＋）。VEGF蛋白定位于细胞浆，胞核无着色。阳性部位主要在上皮中的杯状细胞。翼状胬肉组的染色级别高于对照组（P〈0．05）。结论 VEGF表达增高可能与翼状胬肉发生相关。     

血清IGF-1水平及癌组织VEGF表达在结肠癌患者诊断和治疗中的临床意义

目的探讨血清中胰岛素样生长因子-1（IGF-1）水平及癌组织中血管内皮生长因子（VEGF）表达在结肠癌的诊断和治疗中的临床意义。方法选择处于不同Dukes分期的结肠癌患者80例,并以同期因外伤而切除正常结肠组织的患者20例作为对照组,采用双位点免疫放射测定法和免疫组化法检测患者在结肠癌手术前后血清中IGF-1水平和癌组织中VEGF表达水平,并与对照组进行对比。结果Dukes各期结肠癌患者手术前后血清IGF-1水平均高于对照组,差异有统计学意义（P〈0．05）;各期结肠癌患者术前血清IGF-1水平高于术后水平,差异有统计学意义（P〈0．05）。结肠癌组VEGF弱阳性和阳性患者比例明显高于对照组,差异有统计学差异（P〈0．01）。结论血清IGF-1水平和VEGF表达水平与结肠癌的发病密切相关,有望作为结肠癌发生、发展的预测指标及手术疗效的评价指标。     

肺癌患者血管内皮生长因子和内皮抑素水平变化及意义

目的探讨肺癌患者手术、化疗及联合恩度化疗前后血清血管内皮生长因子(VEGF)和E内皮抑素(ndostatin)水平的变化及临床意义。方法用ELISA法检测20例健康人及20例肺癌患者手术前后和60例肺癌患者化疗及联合恩度前后的血清VEGF和Endostatin水平。结果肺癌组血清VEGF、Endostatin水平明显高于健康人组(P<0.01),其水平与肿瘤大小、临床分期有关,与组织学类型无关(P>0.05)。肺癌患者手术后第1天VEGF水平高于手术前(P<0.01),第7天血清VEGF水平高于手术前和手术后第1天水平(P<0.01)。肺癌患者单独化疗受益组结束后1 d血清内皮抑素水平明显高于化疗前和化疗结束后14 d的水平(P<0.05)。单独化疗无效组第14天血清VEGF水平高于化疗前和化疗后第1天水平(P<0.05)。肺癌患者单独及联合"恩度"化疗受益组治疗后第1天血清VEGF水平低于化疗前(P<0.05),第14天血清VEGF水平低于治疗前和治疗后第1天水平(P<0.05)。联合恩度化疗有效率为56.67%,单独化疗有效率为26.67%(P<0.05),且其有效患者的VEGF水平治疗后明显下降(P<0.05)。结论肺癌患者的血清VEGF和Endostatin水平升高且随临床分期进展和肿瘤直径增大明显升高,并与手术及化疗有关,有助于对肺癌患者的治疗效果和预后进行判断。血清VEGF和Endostatin水平不受病理类型的影响,化疗联合"恩度"治疗肺癌优于单用化疗,血清VEGF水平是疗效监测指标之一。     

Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma

BACKGROUND: The addition of the long-acting beta(2)-adrenergic agonist formoterol to low- to moderate-dose budesonide has shown clinical efficacy in patients with persistent asthma. Combination therapy with budesonide/formoterol in 1 pressurized metered-dose inhaler (pMDI) has been found to have greater efficacy than its monocomponents in patients with moderate to severe persistent asthma, but it has not been assessed in patients with mild to moderate persistent asthma. OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of budesonide and formoterol delivered via 1 pMDI (budesonide/formoterol pMDI), budesonide pMDI, formoterol dry powder inhaler (DPI), and placebo. METHODS: This 12-week, multicenter, double-blind, randomized, placebo-controlled, double-dummy study was conducted at 56 centers across the United States. Patients aged > or =12 years with mild to moderate persistent asthma treated with inhaled corticosteroids (ICSs) for > or =4 weeks before screening and who had a forced expiratory volume in 1 second (FEV(1)) of > or =60% to < or =90% of predicted normal at screening were eligible. After 2 weeks (current asthma therapy discontinued), patients received twice-daily budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations (160/9 microg), budesonide pMDI 80 microg x 2 inhalations (160 microg), formoterol DPI 4.5 microg x 2 inhalations (9 microg), or placebo. The coprimary efficacy variables were changes from baseline in morning predose FEV(1) and 12-hour mean FEV(1) (from serial spirometry) after administration of the morning dose of study medication. Tolerability was assessed based on adverse events (AEs); routine laboratory assessments; electrocardiography; 24-hour Holter monitor assessments; and physical examinations, including vital signs (eg, systolic and diastolic blood pressure and heart rate). AEs were recorded manually by the patient in paper notebooks and reviewed at each clinic visit by the investigator and during a final follow-up phone call. RESULTS: A total of 480 patients were randomized (299 females, 181 males; mean age, 36 years; mean FEV(1), 2.4 L; budesonide/formoterol pMDI, 123 patients; budesonide pMDI, 121; formoterol DPI, 114; placebo, 122). At end of treatment, the mean increases from baseline in predose FEV(1) were greater with budesonide/formoterol pMDI versus budesonide pMDI, formoterol DPI, and placebo (0.37 vs 0.23, 0.17, and 0.03 L, respectively; all, P<0.005). 0.005). After administration of the first dose and at weeks 2 and 12, mean increases in 12-hour mean FEV(1) were significantly greater with budesonide/formoterol pMDI (0.41, 0.47, and 0.50 L, respectively) versus budesonide pMDI (0.17, 0.30, and 0.32 L) and placebo (0.15, 0.12, and 0.12 L) (all, P < 0.001). Fewer patients receiving budesonide/formoterol pMDI met criteria for (18.7%; P < 0.001) or withdrew because of (7.3%; P < or = 0.010) worsening asthma versus formoterol DPI (42.1% and 18.4%, respectively) and placebo (56.6% and 32.8%); results were similar between budesonide pMDI (21.5% and 6.6%, respectively) and budesonide/formoterol pMDI. Three patients experienced serious AEs; none was considered related to study medication. The proportions of withdrawals due to worsening asthma were not significantly different between the budesonide/formoterol pMDI and budesonide pMDI groups. CONCLUSIONS: In this population of adults and adolescents with mild to moderate persistent asthma previously treated with ICSs, twice-daily budesonide/formoterol pMDI was associated with significantly increased pulmonary function versus its monocomponents. All study drugs were generally well tolerated.     

急性白血病患者骨髓VEGF高表达及其与预后的相关性分析

目的:检测非M3型急性白血病(AL)患者的骨髓血管内皮生长因子(VEGF)水平,探讨VEGF的表达水平与预后的关系.方法:选取2016年1月至2019年12月在武威市人民医院血液内科住院的AL患者共114例,以本课题组25名健康志愿者为对照组,用ELISA方法分别检测骨髓VEGF的浓度,依据VEGF表达水平进行分组,比...     

运动训练对大鼠局灶性脑缺血后微血管新生的影响

目的：探讨运动训练对局灶性脑缺血后微血管新生的影响。方法：55只SD大鼠随机分为假手术对照组、模型组、康复组；模型组和康复组动物以线栓法制成大鼠左侧大脑中动脉梗死模型，康复组术后1天开始进行运动训练．每周5天，共4周；其余两组常规饲养。以免疫组织化学法检测血管内皮生长因子（VEGF）、因子表达，测定微血管密度。结果：大鼠大脑中动脉栓塞后，缺血区神经元变性、坏死，VEGF和因子在缺血周边区表达明显增加．经运动训练干预后，VEGF和因子表达大量增加，做血管数目明显增加。结论：运动训练可通过促VEGF表达上调．促进微血管新生。     

颞叶癫痫模型大鼠海马区血管形成素-1、血管内皮 生长因子的表达

目的:探讨颞叶癫痫模型大鼠海马区血管形成素-1(Ang-1)、血管内皮生长因子(VEGF)的表达及其在颞叶癫痫中的作用。方法:选取雄性Wistar大鼠60只,腹腔注射氯化锂-匹罗卡品及生理盐水分别建立颞叶癫痫模型组及对照组;观察大鼠行为学改变,比较2组大鼠海马区Ang-1、VEGF的动态表达过程。结果:模型组均可见动物出现行为呆滞、活动减少、凝视、前肢搔痒样动作或平衡不能等异常表现,部分伴有外周胆碱能反应,但症状程度较轻,持续数十分钟后可自行缓解。对照组动物无抽搐表现。第1小时,模型组的Ang-1表达较对照组减少(P0.05),至第3天降至最低水平,后逐渐升高(P0.05),至18 d接近正常水平(P0.05);VEGF表达第1天升高(P0.05),至第3天升至最高水平(P0.05),后逐渐降低,至18 d接近正常水平(P0.05)。结论:抽搐频繁时,Ang-1表达持续降低,VEGF表达持续升高;抽搐减少时,Ang-1和VEGF表达逐渐恢复正常。Ang-1与VEGF表达呈直线负相关关系。     

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

BACKGROUND: Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide pMDI and budesonide/formoterol dry-powder inhaler (DPI; Turbuhaler). METHODS: This was a 12-week, multinational, randomised, double-blind, double-dummy study involving patients aged > or = 12 years with asthma. All patients had a forced expiratory volume in 1 s of 50-90% predicted normal and were inadequately controlled on inhaled corticosteroids (500-1600 microg/day) alone. Following a 2-week run-in, during which they received their usual medication, patients were randomised (two inhalations twice daily) to budesonide pMDI 200 microg, budesonide/formoterol DPI 160/4.5 microg or budesonide/formoterol pMDI 160/4.5 microg. The primary efficacy end-point was change from baseline in morning peak expiratory flow (PEF). RESULTS: In total, 680 patients were randomised, of whom 668 were included in the primary analysis. Therapeutically equivalent increases in morning PEF were observed with budesonide/formoterol pMDI (29.3 l/min) and budesonide/formoterol DPI (32.0 l/min) (95% confidence interval: -10.4 to 4.9; p = 0.48). The increase in morning PEF with budesonide/formoterol pMDI was significantly higher than with budesonide pMDI (+28.7 l/min; p < 0.001). Similar improvements with budesonide/formoterol pMDI vs. budesonide pMDI were seen for all secondary efficacy end-points. Both combination treatments were similarly well tolerated. CONCLUSIONS: Budesonide/formoterol, administered via the HFA pMDI or DPI, is an effective and well-tolerated treatment for adult and adolescent patients with asthma, with both devices being therapeutically equivalent.     

Symbicort Turbuhaler: a new concept in asthma management

Symbicort is a novel asthma product containing both budesonide and formoterol in a single inhaler, Turbuhaler. Budesonide is a corticosteroid that treats underlying airway inflammation in asthma; formoterol is a rapid- and long-acting beta2-agonist that prevents and reverses airway obstruction. Budesonide and formoterol therefore have complementary effects, treating two different components of asthma. Clinical studies have shown that Symbicort is more effective in the treatment of asthma than double-dose corticosteroid, and clinical experience to date indicates that Symbicort is at least as effective and well tolerated as budesonide and formoterol given in separate inhalers. Symbicort has a fast onset of effect, which may help patients feel more in control of their condition and improve adherence to their medication, and a long duration of effect that allows twice-daily or even once-daily dosing during periods of good control. More convenient treatment represents another important benefit for patients with asthma, as ease of use can also result in improved adherence, leading to better disease control.     

肝源性溃疡黏膜中VEGF、bFGE表达的临床意义

目的 探究肝源性溃疡中胃黏膜组织血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的表达,分析其与病情进展及患者并发症发生率的关系.方法 临床选取2014年7月至2016年5月133例肝硬化伴门静脉高压合并胃或十二指肠溃疡患者,内镜下活检溃疡边缘及正常黏膜组织为对照.采用反转录聚合酶链反应(RT-PCR)技术检测正常胃黏膜(133例)、胃溃疡活动期(GA期52例)、胃溃疡愈合期(GH期45例)、胃溃疡瘢痕期(GS期36例)患者黏膜组织VEGF mRNA、bFGF mRNA的表达情况,并与患者的并发症发生率行Spearman秩相关分析.结果 溃疡边缘组织VEGF mRNA、bFGF mRNA的表达量显著高于正常黏膜组织,差异有统计学意义(P＜0.05);GH、GS期患者VEGF mRNA的表达量明显高于GA期患者,差异有统计学意义(P＜0.05),GS期患者bFGF mRNA的表达量明显高于GA期患者,差异有统计学意义(P＜0.05);Spearman秩相关分析结果示VEGF mRNA、bFGF mRNA的表达量与患者溃疡并发症发生率呈负相关(rs=-0.672,-0.508,P＜0.05).结论 VEGF mRNA、bFGF mRNA在肝源性溃疡的修复过程中可能发挥重要的促进作用,是潜在的临床标志物.     

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

This randomised, double-blind, 6-month study compared budesonide/formoterol for maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/formoterol, both with terbutaline for relief. Following a 2-week run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted, mean inhaled corticosteroid dose 745 microg/day) received budesonide/formoterol 160/4.5 microg one inhalation bid plus additional inhalations as needed, salmeterol/fluticasone 25/125 microg two inhalations bid plus as-needed terbutaline or budesonide/formoterol 320/9 microg one inhalation bid plus as-needed terbutaline. Budesonide/formoterol for maintenance and relief prolonged the time to first severe exacerbation requiring hospitalisation, emergency room treatment or oral steroids (primary variable) vs. fixed-dose salmeterol/fluticasone and budesonide/formoterol (p=0.0034 and p=0.023 respectively; log-rank test). Exacerbation rates were 19, 16 and 12 events/100 patients/6 months for salmeterol/fluticasone, fixed-dose budesonide/formoterol and budesonide/formoterol for maintenance and relief, respectively, [rate reduction vs. fixed-dose salmeterol/fluticasone (0.61; 95% CI 0.49-0.76, p<0.001) and vs. fixed-dose budesonide/formoterol (0.72; 95% CI 0.57-0.90, p=0.0048)]. Budesonide/formoterol maintenance and relief patients used less inhaled corticosteroid vs. salmeterol/fluticasone and fixed-dose budesonide/formoterol patients. All treatments provided similar marked improvements in lung function, asthma control days and asthma-related quality of life. Budesonide/formoterol for maintenance and relief reduces asthma exacerbations and maintains similar daily asthma control at a lower overall drug load compared with fixed-dose salmeterol/fluticasone and budesonide/formoterol.     

Combined budesonide/formoterol turbuhaler treatment of asthma

OBJECTIVE: To provide product information; review and analyze the clinical literature studying combination therapy, budesonide, and formoterol in asthmatics; and to define the role for this therapy in asthma treatment. DATA SOURCES: A MEDLINE search (1990-September 2001) was conducted to identify the primary literature. Bibliographies were reviewed for further relevant citations. STUDY SELECTION/DATA EXTRACTION: All randomized, blinded, controlled studies at least 3 months in duration exploring the efficacy of the combination of budesonide and formoterol (in 1 or separate formulations) compared with other treatments were selected to be included in the review of clinical studies. DATA SYNTHESIS: The combination of budesonide and formoterol was more effective than increasing the dose of budesonide in patients with moderate or severe persistent asthma and in patients with mild asthma not previously controlled with inhaled corticosteroids. Milder corticosteroid-na?ve asthmatics did not derive benefit compared with inhaled corticosteroids alone. CONCLUSIONS: Combination therapy in 1 device is a preferred treatment option in patients with moderate to severe persistent asthma and in those with milder asthma not controlled with inhaled corticosteroids. Advantages of this product include rapid onset of action, long duration of action, and a wide dosing range to assist with titration. Further research is required to evaluate this therapy in asthmatic children <5 years old and in patients with oral corticosteroid-dependent asthma. Investigations into the effect of this combination product on other disease outcomes, such as quality of life and productivity, will further define the role for this drug therapy.     

RT-PCR检测白血病细胞VEGF异构体及其受体基因

目的 建立逆转录-聚合酶链反应(RT-PCR)检测白血病细胞血管内皮生长因子(VEGF)异构体及其受体基因的方法。方法 用TRIZOL试剂提取体外培养的细胞系总RNA,M—MLV逆转录酶生成模板cDNA,PCR扩增VEGF异构体基因以及VEGF受体Flt-1基因,扩增产物用含溴化乙锭的2％琼脂糖凝胶电泳后,直接分析电泳结果。结果 白血病细胞(K562和HL-60)出现3条VEGF条带(516bp、588bp、648bp),分别代表VEGF3种异构体(VEGF121,VEGF145,VEGF165)的基因扩增产物,而人脐静脉血管内皮细胞(ECV304)无VEGF条带出现;此外,2种白血病细胞都可以测出VEGF的Flt-1受体基因,与Flt-1阳性细胞ECV304相似。结论 RT-PCR可用于白血病细胞VEGF多种异构体及其Flt-1受体基因的检测。